Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 20:15, 20 September 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or [[user). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

4-MeO-PCP

Clinical data
ATC code	none
Legal status
Legal status	Not Currently Scheduled
Identifiers
IUPAC name 1--piperidine
CAS Number	2201-35-6 91164-58-8 (hydrochloride)
PubChem CID	11778080
ChemSpider	10526416
CompTox Dashboard (EPA)	DTXSID40176450
Chemical and physical data
Formula	C18H27NO
Molar mass	273.412 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES COc3cccc(c3)C1(CCCCC1)N2CCCCC2
InChI InChI=1S/C18H27NO/c1-20-17-10-8-16(9-11-17)18(12-4-2-5-13-18)19-14-6-3-7-15-19/h8-11H,2-7,12-15H2,1H3 Key:MUZGGFNYVLGUFS-UHFFFAOYSA-N
(verify)

4-Methoxyphencyclidine (methoxydine, 4-MeO-PCP) is a dissociative anesthetic drug with hallucinogenic and sedative effects. It is around the same potency as ketamine, but has slightly different effects due to its altered binding profile at various targets, particularly being somewhat more potent as an NMDA antagonist while having around the same potency as a dopamine reuptake inhibitor.

The positional isomer 3-MeO-PCP is also known. Being around 10 times more potent by weight than the 4-methoxy isomer it has around the same potency as PCP. 4-Meo-PCP was reportedly first sold within the UK from 2008 as a designer drug and research chemical by a company trading under the name CBAY.

See also

• Arylcyclohexylamine
• 3-MeO-PCP

References

1. Vignon J, Vincent JP, Bidard JN, Kamenka JM, Geneste P, Monier S, Lazdunski M (1982). "Biochemical properties of the brain phencyclidine receptor". European Journal of Pharmacology. 81 (4): 531–42. doi:10.1016/0014-2999(82)90342-9. PMID 6214413. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
2. Manallack DT, Wong MG, Costa M, Andrews PR, Beart PM (1988). "Receptor site topographies for phencyclidine-like and sigma drugs: predictions from quantitative conformational, electrostatic potential, and radioreceptor analyses". Molecular Pharmacology. 34 (6): 863–79. PMID 2849051. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
3. Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R (1989). "Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs". Pharmacology, Biochemistry, and Behavior. 32 (3): 699–705. doi:10.1016/0091-3057(89)90020-8. PMID 2544905. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
4. Manallack DT, Davies JW, Beart PM, Saunders MR, Livingstone DJ (1993). "Analysis of the biological and molecular properties of phencyclidine-like compounds by chemometrics". Arzneimittel-Forschung. 43 (10): 1029–32. PMID 8267664. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

This hallucinogen-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Dissociative drugs
• Piperidines
• Phenol ethers
• Hallucinogen stubs